2-(1-methylimidazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid | 118054-35-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物
• 英文名称: 2-(1-methylimidazol-4-yl)-1-hydroxyethane-1,1-diphosphonic acid
• 英文别名: 2-(1-methylimidazol-4-yl)-1-hydroxyethane-1,1-diamine；[1-Hydroxy-2-(1-methylimidazol-4-yl)-1-phosphonoethyl]phosphonic acid
• CAS: 118054-35-6
• 化学式: C₆H₁₂N₂O₇P₂
• 分子量: 286.118
• InChiKey: VSLQUGGYXRLUSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• Method of administering bisphosphonates
  申请人：——

  公开号：US20030181421A1

  公开（公告）日：2003-09-25

  Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, wherein the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.

  双膦酸盐，特别是更强效的N-双膦酸盐，如左氧磷酸和衍生物，可以通过间歇性给药获得令人满意的结果，长期抑制骨质疏松等异常增加骨转换的情况中的骨吸收，例如骨质疏松症，其中双膦酸盐给药之间的间隔时间比以前认为适当的更长，例如至少大约6个月或更少频繁的给药间隔。
• Use of bisphosphonates for pain treatment
  申请人：——

  公开号：US20040063670A1

  公开（公告）日：2004-04-01

  A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient.

  一种用于治疗疼痛的方法，特别是用于需要这种治疗的患者，例如骨质疏松症或骨质疏松症患者、肿瘤患者或患有炎症性疾病的患者的镇痛或抗痛觉过敏治疗，包括向患者施用有效量的双膦酸盐，例如唑来膦酸或其盐或水合物。
• Pharmaceutical products comprising bisphosphonated
  申请人：Glausch Alexandra

  公开号：US20050119230A1

  公开（公告）日：2005-06-02

  A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

  一种药品产品包括一个容器，其中装有双磷酸盐溶液，至少该容器的内表面包括塑料材料，并且该容器可以进行热灭菌处理，该药品产品以输注溶液预浓缩物的形式存在，用于给需要双磷酸盐治疗的患者进行双磷酸盐治疗。
• PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES
  申请人：Glausch Alexandra

  公开号：US20080254089A1

  公开（公告）日：2008-10-16

  A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

  一种制药产品包括一个容器，其中包含一种双磷酸盐溶液，其中至少容器的内表面由塑料材料制成，并且容器可以进行热灭菌处理，该产品以输注溶液预浓缩物的形式提供，用于给需要双磷酸盐治疗的患者进行双磷酸盐治疗。
• BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER
  申请人：Glausch Alexandra

  公开号：US20120027818A1

  公开（公告）日：2012-02-02

  A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

  一种药物制品包括一个容器，其中装有双磷酸盐溶液，至少容器的内表面包括塑料材料，并且容器可以进行热灭菌处理，且该制品是一种输注溶液的预浓缩物，用于给需要双磷酸盐治疗的患者进行治疗。